Alkem Laboratories Limited

Alkem Laboratories Limited

Alkem Laboratories Limited held its 52nd Annual General Meeting on August 27, 2026, through video conferencing. The meeting was attended by 77 members, and all the directors were present. The company provided remote e-voting and e-voting facilities during the meeting. The resolutions related to the audited financial statements, payment of dividends, appointment of directors, and ratification of the cost auditor were passed with the requisite majority.

Alkem Laboratories Limited

Alkem Laboratories Limited has announced its Q1 FY2027 earnings, with revenue from operations at INR3,740 crores, a 11% year-on-year growth, and EBITDA margin at 20.5%, a 3.7% year-on-year growth. The company has outperformed the Indian pharmaceutical market in 7 key focus therapies, with growth rates ranging from 1.1x to 1.6x.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting) for the Scheme of Amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange about the publication of a newspaper advertisement regarding the disclosure of standalone and consolidated financial results for the quarter ended June 30, 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alkem Laboratories Limited

Alkem Laboratories Limited has made available the audio recording of its Q1FY2027 Earnings Conference Call on its website.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure and opening dates pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Alkem Laboratories Limited

Alkem Laboratories has informed the Exchange about the approval of setting up a new block within its existing manufacturing facility at Baddi, Himachal Pradesh, and an investment of up to INR 75 crores.

Alkem Laboratories Limited

Alkem Laboratories Ltd. has announced its Q1FY27 financial results, with a 10.9% YoY growth in total revenue from operations. The company has outperformed the Indian Pharmaceutical Market (IPM) in several key therapies, and has received 05 ANDAs approvals in the US market. The company will hold a conference call on August 14, 2026, to discuss its financial results.

Alkem Laboratories Limited

Alkem Laboratories Limited has submitted the outcome of its Board Meeting held on 14th August, 2026, where the Board approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2026. The results and Limited Review Report of the Statutory Auditors are enclosed.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange about an update on the US FDA inspection at its manufacturing facility located at Amaliya, Daman. The facility received a Form FDA 483 containing seven observations, and the US FDA has classified the inspection status as Official Action Indicated (OAI). The company continues to manufacture and supply approved products from the facility to the U.S. market.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange regarding the appointment of Mr. Rajpal Singh Rana as a senior management personnel, effective from 03rd August, 2026. The details of the appointment are provided in Annexure I to the letter.

Alkem Laboratories Limited

Alkem Laboratories Limited has dispatched letters to shareholders who have not registered their email addresses with the company or depository participants, providing the web-link to access the Annual Report for FY 2025-26.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange about the dispatch of Notice of the 52nd Annual General Meeting (AGM) along with the Annual Report for the financial year 2025-26 and e-voting information.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026, along with the Annual Report for financial year 2025-2026.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange about the Business Responsibility and Sustainability Report for the financial year ended 31st March, 2026.

Alkem Laboratories Limited

Alkem Laboratories Limited has scheduled a conference call on August 14, 2026, to discuss its Q1FY27 financial results.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange regarding the resignation of Dr. Jitendra Singh Huda as a Senior Management Personnel effective July 23, 2026.

Alkem Laboratories Limited

Alkem Laboratories has completed the acquisition of at least 51% of Occlutech Holding AG, a Swiss company, through its subsidiary Alkem Medtech Private Limited.

Alkem Laboratories Limited

Alkem Laboratories Limited has informed the Exchange about a copy of newspaper publication regarding the notice of the meeting of the equity shareholders of Alkem Laboratories Limited being convened pursuant to the order of the Hon’ble National Company Law Tribunal, Mumbai Bench, dated June 10, 2026. The meeting will be held on August 17, 2026, through electronic mode (video conference or other audio visual means) to consider and if thought fit, approve the Scheme of Amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited.

Alkem Laboratories Limited

Alkem Laboratories Limited has acquired 79,36,50,794 equity shares of Alkem Medtech Private Limited at Rs. 13.86 per share, aggregating to Rs. 11,00,00,00,005/-. The acquisition is a rights issue and the shares were allotted on 15th July, 2026.